Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Wisee who wrote (928)	7/28/1998 1:52:00 AM
From: Edward W. Richmond	Respond to of 1185

Wisee, hello again. Did you see the Investors-On-Line presentation by Robert Rieder? I don't think there was any mention made of the recently started Phase II clinical trials for the local anaesthetic compound RSD921. It would seem that this level in the approval process would enhance the image of the company to investors watching the program. My recollection is that all the discussion was of preclinical compounds, which would, in my opinion, portray Nortran as an earlier stage biotech company than it actually is. I would appreciate any information/correction you can provide. Regards, Ed P.S. I certainly have not changed my opinion about Nortran. I am simply trying to rationalize the market action subsequent to Robert Rieder's presentation